Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1097-1107

  Ginsberg, Lawrence ^a   Katic, Alain ^b   Adeyi, Ben ^c   Dirks, Bryan ^c   Babcock, Thomas ^c   Lasser, Robert ^c   Scheckner, Brian ^c   Adler, Lenard A ^d  

^a Red Oak Psychiatry Associates   (United States)

^b Claghorn Lesem Research Clinic Ltd   (United States)

^c SHIRE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADHD RS IV; Adult; Attention deficit hyperactivity disorder (ADHD); Clinical Global Impressions; Lisdexamfetamine dimesylate (LDX); Severity

Indexed keywords

LISDEXAMFETAMINE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; LONG TERM CARE; OPEN STUDY; PATIENT SELECTION; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DEXTROAMPHETAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79956157477     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.567256     Document Type: Article

References (40)

1. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26-49S
2. Dulcan M, and the Work Group on Quality Issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997;36:85-121S
3. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry 2005;57:1442-51 (Pubitemid 40798566)
4. Lara C, Fayyad J, De Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry 2009;65:46-54
5. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-23 (Pubitemid 44464584)
6. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40 (Pubitemid 43764229)
7. Biederman J, Petty CR, Fried R, et al. Educational and occupational under-attainment in adults with attention-deficit/hyperactivity disorder: a controlled study. J Clin Psychiatry 2008;69:1217-22
8. Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97-107 (Pubitemid 46043846)
9. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/ hyperac-tivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2006;256(Suppl 1): i26-31
10. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991;48:851-5
11. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 2007;11:351-62
12. Adler LA, Spencer TJ, Levine LR, et al. Functional outcomes in the treatment of adults with ADHD. J Atten Disord 2008;11:720-7
13. Escobar R, Montoya A, Polavieja P, et al. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:253-63
14. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry 2001;40:922-8 (Pubitemid 32667075)
15. Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987;17:121-43 (Pubitemid 17055159)
16. Denney CB, Rapport MD. Predicting methylphenidate response in children with ADHD: theoretical, empirical, and conceptual models. J Am Acad Child Adolesc Psychiatry 1999;38:393-401 (Pubitemid 29153110)
17. Steele M, Jensen PS, Quinn DMP. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther 2006;28: 1892-908 (Pubitemid 46038524)
18. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl16):5-9
19. KeckJr PE, McElroySL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155:646-52 (Pubitemid 28225405)
20. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000;157:816-8 (Pubitemid 30249663)
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-III-R. 3rd edn. Washington, DC: American Psychiatric Association, 1987
22. Stein MA. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care2004;10(Suppl):S89-98 (Pubitemid 38970244)
23. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother 2008;9:1565-74 (Pubitemid 352005916)
24. Adler LA, Goodman DW, Kollins SH, et al, on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:1364-73
25. Wigal T, Brams M, Gasior M, et al.; on behalf of the 316 Study Group. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct 2010;6:34
26. Weisler R, Young J, Mattingly G, et al.; on behalf of the 304 Study Group. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr 2009;14:573-85
27. American Psychiatric Association. Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th edn. Text Revision. Washington, DC: American Psychiatric Association, 2000
28. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-201 (Pubitemid 38452762)
29. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976:218-22
30. Young J, Mattingly G, Weisler R, et al. Response and symptomatic remission in a long-term trial of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: American Psychiatric Association's 162nd Annual Meeting; May 16-21, 2009; San Francisco, CA, USA
31. Swanson JM, KraemerHC, HinshawSP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001;40:168-79 (Pubitemid 32111020)
32. Mattingly G, Weisler R, Young J, et al. Response and symptomatic remission in short-and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: US Psychiatric and Mental Health Congress Conference and Exhibition; November 2-5, 2009; Las Vegas, NV, USA
33. Stein MA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003;112:e404-13
34. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-901 (Pubitemid 35283256)
35. KelseyDK, Sumner CR, CasatCD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
36. Swanson J, Lerner M, March J, et al. Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study. Pediatr Clin North Am 1999;46:993-1009 (Pubitemid 29477886)
37. Ginsberg LD, Schreckengost J, Krishnan S. Effect of lisdexamfetamine dimesylate on parent-rated measures of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 12 years with ADHD: A Secondary Analysis. Poster presented at: 20th Annual U.S. Psychiatric and Mental Health Congress; October 11-14, 2007; Orlando, FL
38. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009;119:7-14
39. Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol 2010;25:157-73
40. Sciberras E, Roos LE, Efron D. Review of prospective longitudinal studies of children with ADHD: mental health, educational, and social outcomes. CurrAtten Disord Report 2009;1:171-7